Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 5/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117376 | 1.00 | CTSL (0.49) | CTSLERAP2ERAP1LNPEPNPY4R | |
| SCHEMBL22117808 | 0.97 | CTSL (0.51) | CTSLNPY4RPTGER4NPY1RNPY2R | |
| SCHEMBL22117811 | 0.97 | CTSL (0.51) | CTSLNPY4RPTGER4NPY1RNPY2R | |
| SCHEMBL22117557 | 0.97 | CTSL (0.51) | CTSLNPY4RPTGER4NPY1RNPY2R | |
| SCHEMBL22117556 | 0.97 | CTSL (0.51) | CTSLNPY4RPTGER4NPY1RNPY2R | |
| SCHEMBL25382492 | 0.92 | ERAP2 (0.45) | CTSLERAP2ERAP1LNPEPNPY4R | |
| SCHEMBL25382487 | 0.92 | ERAP2 (0.45) | CTSLERAP2ERAP1LNPEPNPY4R | |
| SCHEMBL31679039 | 0.92 | KLK7 (0.49) | CTSLNPY4RNPFFR1NPFFR2 | |
| SCHEMBL30341831 | 0.92 | KLK7 (0.49) | CTSLNPY4RNPFFR1NPFFR2 | |
| SCHEMBL28652171 | 0.91 | CTSL (0.44) | CTSLERAP2ERAP1LNPEPNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| EP-3898652-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | CTSL 273/4885ERAP2 184/4885ERAP1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.